BAR1 LIFE Stock Australian S.E.

BD1

Pharmaceuticals

End-of-day quote Australian S.E. Other stock markets			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-

06-24	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-17	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI

INOVIQ Ltd is an Australia-based biotechnology company developing diagnostics and therapeutics for cancer. The Company's commercialized products include EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The Company is also advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1900AUD

Average target price

0.7000AUD

Spread / Average Target

+268.42%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

As early as today, start finding the best investment opportunities!

Market Cap	26.75M 18.88M 16.36M 15.32M 13.98M 26.31M 1.8B 180M 70.38M 902M 70.9M 69.36M 3.01B	P/E 2026 *	-4.75x	P/E 2027 *	-4.75x
Enterprise Value	26.75M 18.88M 16.36M 15.32M 13.98M 26.31M 1.8B 180M 70.38M 902M 70.9M 69.36M 3.01B	EV / Sales 2026 *	29.7x	EV / Sales 2027 *	19.1x
Free-Float	66.05%	Yield 2026 *	-	Yield 2027 *	-

06-24	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-17	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI
12-22	INOVIQ Appoints Chief Scientific Officer	MT
12-22	INOVIQ Limited Announces Management Changes, Effective January 12, 2026	CI
12-17	Inoviq says Peter Gunzburg elected to role of chairman	RE
11-27	Inoviq Ltd Elects Peter Gunzburg as Non-Executive Director	CI
11-27	Inoviq says chairman David Williams to step down at year-end	RE
25-10-16	INOVIQ Ltd Announces Appointment of Peter Gunzburg as A Non-Executive Director, Effective 20 October 2025	CI
25-10-12	Inoviq completes A$9.5 million placement	RE
25-10-08	Inoviq Ltd seeks trading halt	RE
25-09-25	INOVIQ Secures Worldwide License for Development, Commercialization of Ovarian Cancer Detection Biomarkers; Shares Jump 5%	MT
25-09-25	Inoviq licences worldwide rights to ovarian cancer biomarker IP from UniQuest	RE
25-08-21	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2025	CI

23-07-07	INOVIQ AND PROMEGA ANNOUNCE GLOBAL JOINT MARKETING AGREEMENT FOR EXO-NET EXOSOME ISOLATION AND NUCLEIC ACID PURIFICATION SOLUTIONS	AQ
22-07-26	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - June 2022	PU
22-04-28	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - March 2022	PU
22-04-05	INOVIQ : Updated Investor Presentation	PU
21-12-06	BARD1 Life Sciences : Application for quotation of securities - BD1	PU

Manager	Title	Age	Since
Leearne Hinch CEO	Chief Executive Officer	-	2016-11-06
Mark Edwards DFI	Director of Finance/CFO	-	2022-11-01
Rebecca Lim CTO	Chief Tech/Sci/R&D Officer	-	2026-01-11

Director	Title	Age	Since
Philip Powell BRD	Director/Board Member	67	2019-06-17
Robert Johnston BRD	Director/Board Member	-	2019-06-17
Geoff Cumming CHM	Chairman	-	2020-07-27

BAR1 LIFE Stock Australian S.E.

Stocks

BD1

Pharmaceuticals

Valuation: BAR1 LIFE

Latest news : BAR1 LIFE

Press Releases: BAR1 LIFE

Managers and Directors: BAR1 LIFE

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAR1 LIFE	-.--%	-.--%	-	-	19.89M
ELI LILLY AND COMPANY	-0.75%	+9.75%	+92.77%	+131.79%	1,098B
JOHNSON & JOHNSON	-1.24%	+1.65%	+49.08%	+49.05%	631B
ABBVIE INC.	+0.02%	+1.72%	+24.85%	+62.97%	438B
ROCHE HOLDING AG	-1.13%	+3.13%	+49.78%	+39.13%	368B
NOVARTIS AG	-0.74%	+1.01%	+31.08%	+38.64%	298B
ASTRAZENECA PLC	-1.22%	+0.89%	+7.32%	+7.38%	251B
AMGEN INC.	-0.86%	+6.01%	+45.03%	+57.51%	226B
NOVO NORDISK A/S	+0.34%	-0.13%	-4.77%	-50.50%	209B
GILEAD SCIENCES, INC.	+1.45%	-0.06%	+12.20%	+68.96%	165B
Average	-0.37%	+1,657.21%	+34.15%	+44.99%	409.37B
Weighted average by Cap.	-0.63%	+1,331.50%	+50.03%	+66.45%

	2026 *	2027 *
Net sales	900K 635K 551K 515K 470K 885K 60.61M 6.04M 2.37M 30.33M 2.39M 2.33M 101M	1.4M 988K 857K 802K 732K 1.38M 94.27M 9.4M 3.68M 47.19M 3.71M 3.63M 157M
Net income	-	-
Net Debt	-	-